NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and

Stuart Tugendreich1, Cecelia I Pearson, John Sagartz

  • 1Iconix Pharmaceuticals Inc., Mountain View, California 94043, USA.

Toxicologic Pathology
|April 29, 2006
PubMed

Insights

Non-steroidal anti-inflammatory drugs (NSAIDs) can trigger a systemic inflammatory response by increasing gut permeability and allowing lipopolysaccharide (LPS) into circulation. Hepatic gene expression serves as an early biomarker for this acute phase response (APR).

Area of Science:

  • Toxicogenomics
  • Pharmacology
  • Biomarker Discovery

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) are known to cause gastrointestinal injury.
  • NSAID-induced intestinal injury may lead to increased intestinal permeability, allowing lipopolysaccharide (LPS) translocation.
  • This translocation can trigger a systemic acute phase response (APR) detectable in the liver.

Purpose of the Study:

  • To investigate the relationship between NSAID-induced gastrointestinal injury and the acute phase response (APR).
  • To evaluate hepatic gene expression as an early biomarker for NSAID-induced APR.
  • To assess the gastrointestinal safety profiles of various NSAIDs.

Main Methods:

  • A short-term study in rats treated with aspirin, indomethacin, ibuprofen, and rofecoxib.
  • Examination of serum inflammatory cytokines, histologic evaluation, and hepatic gene expression.
  • Analysis of serum LPS levels and gastrointestinal pathology.

Main Results:

  • Indomethacin and ibuprofen caused gastrointestinal injury, induced APR, and increased serum LPS levels.
  • Aspirin and rofecoxib did not significantly affect the gastrointestinal tract or induce APR.
  • Hepatic gene expression of inflammatory genes was altered as early as 6 hours post-treatment, preceding traditional clinical pathology markers.
  • A hepatic gene expression biomarker for APR was developed, demonstrating early identification of inflammatory injury.

Conclusions:

  • NSAID-induced intestinal injury leads to LPS translocation, provoking a systemic inflammatory response.
  • Hepatic gene expression serves as an early and sensitive biomarker for the onset of APR.
  • Significant differences in gastrointestinal safety were observed among the studied NSAIDs, with rofecoxib showing a wider margin between efficacious and APR-inducing doses.

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Acute Inflammation I: Inflammatory Response01:26

Acute Inflammation I: Inflammatory Response

Acute inflammation is a rapid, short-lived physiological response to tissue injury or infection, designed to eliminate harmful agents and initiate repair. This tightly regulated process typically lasts from minutes to several days and is triggered by factors such as microbial invasion, physical trauma, or chemical injury.Recognition and Mediator ReleaseThe inflammatory response begins when resident immune cells—such as mast cells, macrophages, and dendritic cells—detect damage-associated...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Acute Inflammation II: Cellular Phase01:26

Acute Inflammation II: Cellular Phase

The cellular phase of acute inflammation is a tightly orchestrated sequence of events that recruits leukocytes, primarily neutrophils, to sites of tissue injury or infection. Following the initial vascular changes, this phase ensures effective immune cell migration, activation, and function at the affected site to eliminate pathogens and initiate tissue repair.Leukocyte Recruitment CascadeLeukocyte recruitment happens in four steps: margination, adhesion, transmigration, and chemotaxis. Reduced...